Given macrocytosis, elevated BUN, stage 3 chronic kidney disease (eGFR ≈ 47 mL/min), borderline‑high cholesterol, and vitamin D deficiency, what is the likely diagnosis and recommended treatment?

Stage 3 Chronic Kidney Disease with Macrocytic Anemia and Vitamin D Deficiency

You have Stage 3 chronic kidney disease (CKD) with macrocytic anemia (likely multifactorial from B12/folate deficiency and/or kidney disease itself), vitamin D deficiency, and borderline dyslipidemia requiring immediate vitamin D supplementation, further anemia workup, statin therapy, and nephrology referral.

Primary Diagnoses

Your lab values indicate:

• Stage 3a CKD: eGFR 47.4 mL/min/1.73 m² with elevated BUN (30 mg/dL) 1
• Macrocytic anemia: MCV 104.8 fL (>100 fL defines macrocytosis) 2
• Vitamin D deficiency: 19.8 ng/mL (target >30 ng/mL) 3
• Borderline hypercholesterolemia: Total cholesterol 207 mg/dL
• Low MCHC: 30.5 g/dL suggests possible hemoglobin concentration issues

Immediate Treatment Plan

1. Vitamin D Supplementation (Priority #1)

Start ergocalciferol (vitamin D2) 50,000 IU weekly for 12 weeks, then monthly maintenance 3. This is the preferred formulation for CKD patients with GFR 20-60 mL/min/1.73 m² and vitamin D levels <30 ng/mL 3.

• Your level of 19.8 ng/mL indicates true deficiency requiring aggressive repletion
• Target 25-OH vitamin D >30 ng/mL (some evidence suggests >27 ng/mL for optimal bone health in CKD) 4
• Monitor serum calcium and phosphorus every 3 months during therapy 3
• Critical safety point: Discontinue if calcium exceeds 10.2 mg/dL or phosphorus exceeds 4.6 mg/dL 3
• Avoid mega-doses (≥100,000 IU boluses) which increase toxicity risk 5

2. Macrocytic Anemia Workup (Priority #2)

Your MCV of 104.8 fL requires immediate investigation 2, 6:

Order these tests now:

• Vitamin B12 level
• Folate level
• Reticulocyte count (corrected for anemia)
• Complete blood count with differential
• Peripheral blood smear
• Consider thyroid function tests (hypothyroidism causes macrocytosis)

Macrocytosis in your context suggests:

• Vitamin B12 or folate deficiency (most common megaloblastic cause) 2
• Anemia of chronic kidney disease 2
• Medication effect if on any drugs like hydroxyurea
• Less commonly: hypothyroidism, alcohol use, myelodysplastic syndrome 2

Next steps based on results:

• If B12 <200 pg/mL: Start B12 supplementation (1000 mcg IM or high-dose oral)
• If folate deficient: Start folic acid 1 mg daily
• If reticulocyte count is low with normal B12/folate: Consider bone marrow evaluation for CKD-related anemia or myelodysplasia 7

3. Statin Therapy (Priority #3)

Start a moderate-to-high intensity statin immediately 8. With eGFR <60 mL/min/1.73 m² and age likely ≥50 years (based on CKD presence), you meet criteria for statin therapy regardless of cholesterol level 8.

• Recommended: Atorvastatin 20-40 mg daily or rosuvastatin 10-20 mg daily
• Cholesterol 207 mg/dL is borderline high, but cardiovascular risk from CKD itself mandates treatment 8
• No dose adjustment needed for Stage 3 CKD

4. CKD Management

Essential monitoring and interventions:

• Blood pressure control: Target <140/90 mmHg; if albuminuria present, consider ACE inhibitor or ARB 1
• Check urine albumin-to-creatinine ratio (ACR) if not already done—critical for CKD staging and treatment decisions 1
• Avoid nephrotoxins: NSAIDs, certain antibiotics, contrast dye when possible 9
• Monitor electrolytes: Check potassium, bicarbonate, calcium, phosphorus every 3-6 months 10
• Screen for complications: Anemia (already present), metabolic acidosis, secondary hyperparathyroidism 10

5. Nephrology Referral

You need nephrology consultation given eGFR 47.4 mL/min/1.73 m² (Stage 3a CKD) 1, 9. While not immediately urgent, referral is appropriate for:

• CKD management optimization
• Anemia evaluation and potential treatment
• Vitamin D/mineral metabolism monitoring
• Cardiovascular risk reduction strategies

Common Pitfalls to Avoid

1. Do NOT use calcitriol or active vitamin D analogs for simple vitamin D deficiency—these are reserved for secondary hyperparathyroidism with PTH >300 pg/mL 3

2. Do NOT ignore the macrocytosis—while CKD can cause normocytic anemia, MCV >100 fL demands B12/folate evaluation 2

3. Do NOT delay statin therapy waiting for "lifestyle modifications"—CKD itself is a cardiovascular disease equivalent 8

4. Do NOT supplement calcium without checking PTH and phosphorus first—risk of vascular calcification in CKD 3

5. Monitor for hypercalcemia during vitamin D repletion—CKD patients have impaired calcium excretion 3

Follow-Up Timeline

• 4 weeks: Recheck vitamin B12, folate, reticulocyte count results; adjust treatment
• 3 months: Recheck 25-OH vitamin D, calcium, phosphorus, lipid panel, complete metabolic panel 3
• 6 months: Reassess eGFR, urine ACR, hemoglobin, continue monitoring 1
• Annually: Once stable, continue vitamin D (monthly 50,000 IU), monitor kidney function, adjust medications as needed 3